Findings from a multi-center, international clinical trial reported by a Cleveland Clinic physician show that semaglutide reduced cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease who do not have diabetes.
Is CG Oncology’s IPO a benchmark for a better year in public offerings?
NEW YORK — CG Oncology rang the Nasdaq opening bell on Thursday morning, marking a rare sight for biotechs over the past two years as
January 26, 2024